Agreed. In practice, many drug/biotech collaborations are tantamount to options insofar as the licensee often has the contractual right to terminate the relationship with relatively minor financial penalties.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”